You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
健世科技-B(09877.HK):LUX-VALVE PLUS TRAVEL II結果於2023年美國經導管心血管治療大會上發佈
格隆匯 10-31 07:06

格隆匯10月31日丨健世科技-B(09877.HK)發佈公吿,近期,LuX-Valve Plus經血管三尖瓣置換系統多中心臨牀試驗(“TRAVEL II”)結果於2023年美國經導管心血管治療大會(Transcatheter Cardiovascular Therapeutics,“TCT”)上由復旦大學附屬中山醫院葛均波院士正式發佈。

TRAVELII是一項前瞻性、多中心、單臂臨牀試驗,主要用於評估LuX-Valve Plus於重度三尖瓣反流患者中應用的長期安全性及有效性。TRAVEL II臨牀試驗已納入中國15家中心的96例患者,所發佈的一個月臨牀數據主要終點為手術後30天覆合事件發生率。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account